From: International comparison of the factors influencing reimbursement of targeted anti-cancer drugs
Drug | Indications | ICER ( in US$) * |
---|---|---|
Nilotinib | Chronic myeloid leukemia, chronic phase: 1st-line | 17,314 |
Imatinib | Gastrointestinal stromal tumor: Adjuvant therapy | 29,591 |
Cetuximab | Colorectal cancer (K-RAS wild type): 1st line with oxaliplatin, fluorouracil, and folinic acid | 42,026 |
Pemetrexed | NSCLC (for non-squamous histology): 1st line with cisplatin | 44,451 |
Lenalidomide | Multiple myeloma: 1st-line | 68,941 |
Pemetrexed | NSCLC: Maintenance treatment | 73,978 |
Sorafenib | Liver cancer: 1st line | 82,792 |
Sunitinib | Renal cell carcinoma: 1st line | 85,572 |
Lapatinib | Breast cancer with HER2 overexpression: 2nd line with capecitabine | 93,496 |
Bevacizumab | Colorectal cancer: with irinotecan, fluorouracil, and leucovorin | 98,937 |
Bevacizumab | Colorectal cancer: with oxaliplatin, fluorouracil, and folinic acid | 110,967 |
Dasatinib | Chronic myeloid leukemia, chronic phase: 1st-line | 118,050 |
Cetuximab | Colorectal cancer: with irinotecan | 121,528 |
Temsirolimus | Renal cell carcinoma: 1st-line for poor prognosis patients | 128,595 |
Bevacizumab | Renal cell carcinoma: 1st line with interferon-α | 131,070 |
Crizotinib | NSCLC (ALK fusion positive): 2nd line (vs. docetaxel) | 158,133 |
Bevacizumab | NSCLC: 1st line with platinum-based chemotherapy | 196,000† |
Cetuximab | Head and neck cancer (squamous cell carcinoma) : 1st line with platinum-based chemotherapy | 261,767 |
Erlotinib | Pancreatic cancer: 1st line with gemcitabine | 430,000‡ |